Are Nanoparticles the Answer to the Question: Is it Working? An Interview with MRA Young Investigator, Dr. Ashish Kulkarni

By Cody R. Barnett, MRA Director of Communications | 4 October 2017 In Science

When we think about cancer researchers, we don’t always think of engineers. Dr. Ashish Kulkarni proves that maybe, we should. His pioneering work as a chemical engineer is helping us answer the critical, yet difficult to answer question that is at the forefront of every patient’s mind as they start treatment: ‘is it working?’

Read More


‘Practice Changing’ Results Hint at New Adjuvant Therapy Treatment Options

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 September 2017 In Treatment

Adjuvant treatment is used in addition to tumor removal e.g. via surgery or radiotherapy to help delay or prevent the recurrence of melanoma. It is often recommended for high-risk melanoma (defined as melanoma deeper or thicker than 4mm thick at the primary site or involves nearby lymph nodes). Approved adjuvant therapies in melanoma include interferon and, more recently, ipilimumab. But neither of these approaches is wholly satisfying since relatively few patients appear to benefit and side-effects are a major factor.

Read More


A Mother’s Perspective: New Options for Pediatric Melanoma

By Cody R. Barnett, MRA Director of Communications | 6 September 2017 In Melanoma Stories, News, Treatment

When Cheryl Trocke’s nine-year old son Graham was diagnosed with melanoma four years ago, she quickly learned that when it comes to kids, there were no great treatment options and that care can vary greatly based on where your child is treated. After surgically removing the primary tumor, Graham’s doctors suggested a treatment plan of ‘wait and see.’

Read More


Measuring Progress: Skin Cancer Prevention in the United States

By Cody R. Barnett, MRA Director of Communications | 6 September 2017 In News, Prevention, Science

On July 29 2014, Dr. Boris Lushniak, the then acting U.S. Surgeon General at, issued a landmark call to action when he declared skin cancer as a major public health problem. He called on everyone, from government agencies to community-based organizations to schools to come together to increase awareness of skin cancer and ways to reduce risk. Since the Call to Action, The Centers for Disease Control and Prevention (CDC) has released an annual report each year documenting progress, celebrating success, and identifying areas where improvement is needed. The key areas of the Call to Action and the update from the CDC 2017 Progress Report are highlighted below.

Read More


Doubling Down: Brandon Barniea Bets Big on Combination Therapy

By Cody R. Barnett, MRA Director of Communications | 6 September 2017 In Melanoma Stories, Treatment

Brandon Barniea didn’t believe he needed to visit doctors. The athletic 35-year-old had always been healthy – even when his wife and two kids were sick at home with the flu, he would miraculously avoid falling ill. So, when he found what felt like “beads” in his neck, reality came crashing in; following a biopsy, he was diagnosed first with stage III melanoma in August 2015 and later that year it progressed to stage IV.

Read More


L’Oréal Paris USA-MRA Team Scientists shed light on how melanoma spreads

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 29 August 2017 In Allies & Partnerships, Science, Treatment

MRA is extremely proud of the 289 investigators we have funded over the last decade and the exciting advances they have made toward ending suffering and death due to melanoma. While we can never highlight all of them at one time, we’re excited in this blog to highlight the work of the L’Oreal Paris USA sponsored MRA Team award.

Read More


Why so much excitement about CAR-T cells?

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 18 July 2017 In News, Science, Treatment

July 12, 2017, marked a historic day for medicine and for the US Food and Drug Administration (FDA) when an expert advisory committee to the FDA unanimously endorsed the first ever genetically engineered, cell-based therapy for use in patients.

Read More


Melanoma Treatments: Breakthroughs for Multiple Cancers — for Real and Right Now

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 July 2017 In Science, Treatment

While 2014 and 2015 offered a whirlwind of good news related to new melanoma treatments from immune to targeted therapy, since then, it’s been a bit quieter in melanoma. Although there has been exceptional news in regard to other cancers. Why is that, and what are the latest breakthroughs?

Read More


Sunscreen Laws may Hinder Protecting Children from Exposure

By Pamela Goldsmith, MRA Director of Communications | 10 July 2017 In News, Policy, Prevention

With the launch of summer comes conventional discussion around ranking sunscreens, and chatter between the experts to parse what should be considered in choosing the most effective among them. It’s also a key conversation among parents heading into the season with an eye on protecting their children from sun exposure. Yet, something remaining a central concern among those parents is the public policy surrounding use of sunscreen in schools.

Read More


Melanoma Research Alliance and the American Cancer Society Forge Research Partnership to Maximize Immunotherapy Benefit to Patients

By Pamela Goldsmith, MRA Director of Communications | 10 July 2017 In Allies & Partnerships, Science

The Melanoma Research Alliance (MRA) and the American Cancer Society (ACS) are partnering to fund much-needed research aimed at decreasing rare, but serious, side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefit to patients.

Read More


Login

×